Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Regulus Therapeutics (RGLS) Misses Q1 EPS by 7c
May 9, 2024 4:44 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q1 EPS of ($0.29), $0.07 worse than the analyst estimate of ($0.22).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More